A Zoghlami1, F Roussel2, J-C Sabourin2, J-M Kuhn3, J-P Marie1, D Dehesdin1, O Choussy4. 1. Service d'ORL et de chirurgie cervico-faciale, hôpital Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen cedex, France. 2. Service d'anatomo-pathologie, hôpital Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen cedex, France. 3. Service d'endocrinologie, hôpital Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen cedex, France. 4. Service d'ORL et de chirurgie cervico-faciale, hôpital Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen cedex, France. Electronic address: olivier.choussy@chu-rouen.fr.
Abstract
OBJECTIVES: BRAF pV600E mutation is the most common oncogenic event and the most specific mutation for papillary thyroid carcinoma (PTC). Many studies over the last decade have shown a direct relationship between BRAF mutation and aggressive tumour characteristics, resulting in poor prognosis. However, several recent studies have suggested that BRAF mutation is not associated with poor prognosis of PTC. The present study was designed to evaluate the association between BRAF mutation with clinicopathological factors and tumour recurrence. MATERIAL AND METHODS: In this retrospective study, BRAF mutation status was examined by direct sequencing on paraffin-embedded tumour specimens from 46 patients undergoing surgery for PTC in our institution from 1985 to 2000. The relationship between BRAF mutation and gender, advanced age, extrathyroid extension, multifocal tumour, cervical lymph node metastasis, tumour size and advanced pT stage of PTC and its predictive role for the risk of tumour recurrence were investigated with a median follow-up of 10.1 (±6.5)years. RESULTS: BRAF mutation was detected in 20 of the 46 patients (43.5%) included in the study. No statistically significant correlation was demonstrated between the presence of BRAF mutation and the various clinicopathological factors studied. No significant difference in tumour recurrence rate or radioiodine sensitivity was observed between the two subgroups: mutant BRAF and wild-type BRAF. CONCLUSION: Although BRAF mutation appears to play a role in local tumour progression, it is not a risk factor for poor prognosis or tumour recurrence in PTC.
OBJECTIVES:BRAF pV600E mutation is the most common oncogenic event and the most specific mutation for papillary thyroid carcinoma (PTC). Many studies over the last decade have shown a direct relationship between BRAF mutation and aggressive tumour characteristics, resulting in poor prognosis. However, several recent studies have suggested that BRAF mutation is not associated with poor prognosis of PTC. The present study was designed to evaluate the association between BRAF mutation with clinicopathological factors and tumour recurrence. MATERIAL AND METHODS: In this retrospective study, BRAF mutation status was examined by direct sequencing on paraffin-embedded tumour specimens from 46 patients undergoing surgery for PTC in our institution from 1985 to 2000. The relationship between BRAF mutation and gender, advanced age, extrathyroid extension, multifocal tumour, cervical lymph node metastasis, tumour size and advanced pT stage of PTC and its predictive role for the risk of tumour recurrence were investigated with a median follow-up of 10.1 (±6.5)years. RESULTS:BRAF mutation was detected in 20 of the 46 patients (43.5%) included in the study. No statistically significant correlation was demonstrated between the presence of BRAF mutation and the various clinicopathological factors studied. No significant difference in tumour recurrence rate or radioiodine sensitivity was observed between the two subgroups: mutant BRAF and wild-type BRAF. CONCLUSION: Although BRAF mutation appears to play a role in local tumour progression, it is not a risk factor for poor prognosis or tumour recurrence in PTC.
Authors: Mourad Zerfaoui; Koji Tsumagari; Eman Toraih; Youssef Errami; Emmanuelle Ruiz; Mohammed Sohail M Elaasar; Moroz Krzysztof; Andrew B Sholl; Sameh Magdeldin; Mohamed Soudy; Zakaria Y Abd Elmageed; A Hamid Boulares; Emad Kandil Journal: Am J Cancer Res Date: 2022-07-15 Impact factor: 5.942
Authors: Suhail Al-Salam; Charu Sharma; Bachar Afandi; Khaled Al Dahmani; Ali S Al-Zahrani; Amal Al Shamsi; Juma Al Kaabi Journal: PLoS One Date: 2020-04-21 Impact factor: 3.240
Authors: Sarah Siraj; Tariq Masoodi; Abdul K Siraj; Saud Azam; Zeeshan Qadri; Sandeep K Parvathareddy; Rong Bu; Khawar S Siddiqui; Saif S Al-Sobhi; Mohammed AlDawish; Khawla S Al-Kuraya Journal: Cancers (Basel) Date: 2022-03-21 Impact factor: 6.639